Scinai Immunotherapeutics (SCNI) Total Debt (2018 - 2026)

Scinai Immunotherapeutics (SCNI) has 9 years of Total Debt data on file, last reported at $641000.0 in Q1 2026.

• For the quarter ending Q1 2026, Total Debt changed N/A year-over-year to $641000.0; the trailing twelve-month figure through Mar 2026 stood at $641000.0 (changed N/A YoY), and the FY2025 full-year result was $623000.0, down 8.92% from the prior year.
• Total Debt improved to $641000.0 in Q1 2026, from $623000.0 in the prior quarter.
• In the past five years, Total Debt ranged from a high of $23.7 million in Q2 2023 to a low of $623000.0 in Q4 2025.
• A 5-year average of $13.6 million and a median of $19.0 million in 2023 frame the typical range for Total Debt.
• Across the five-year window, Total Debt sank 99.98% in 2022 and jumped 44.21% in 2023, its largest moves.
• Tracing SCNI's Total Debt over 5 years: stood at $20.5 million in 2022, then fell by 3.42% to $19.8 million in 2023, then slumped by 96.54% to $684000.0 in 2024, then fell by 8.92% to $623000.0 in 2025, then grew by 2.89% to $641000.0 in 2026.
• Business Quant data shows SCNI's Total Debt at $641000.0 in Q1 2026, $623000.0 in Q4 2025, and $790000.0 in Q2 2025.